Mibefradil is a recently introduced calcium antagonist that, as a tetralol derivative, is
chemically distinct from previous calcium antagonists. This article will review pertinent …

Mibefradil is the prototype of a new class of calcium antagonists that selectively block T‐type
voltage‐gated plasma membrane calcium channels in vascular smooth muscle. The drug is …

Calcium antagonists are an established therapy for patients with hypertension and angina
pectoris, but their current usage is often limited by their pharmacologic profiles and side …

Mibefradil is a new cardiovascular drug with peculiar Ca++ antagonistic properties. The
most remarkable feature of mibefradil is its unique relative selectivity for T type calcium …

Mibefradil, a calcium T-and L-channel blocker developed for use in hypertension, was
recently removed from the market after reports of severe drug-drug interactions. Mibefradil is …

L‐and T‐type voltage‐dependent transmembrane calcium channels are important for
normal functioning of the cardiovascular system. T‐type channels are a heterogeneous …

The mechanisms of nonlinear pharmacokinetics after single-and multiple-dose treatments
with a new calcium channel blocker, mibefradil, were studied. Four female, chronically …

Abstract Effects of bepridil on the low voltage-activated T-type Ca2+ channel (CaV3. 2)
current stably expressed in human embryonic kidney (HEK)-293 cells were examined using …

Low-voltage–activated T-type Ca 2+ channelsare present in most excitable tissues including
the heart (mainly pacemakercells), smooth muscle, central and peripheral nervous systems …

An influx of calcium ions into cells, made possible by the opening of specific, voltage-gated
channels, triggers muscular contraction and several other physiological processes. Two …